Pfizer CEO says COVID-19 vaccine likely to be ready by October this year; 'will have enough evidence of safety, efficacy'
Pfizer is working with German firm Biontech for several possible vaccines in Europe and the United States, said the report.
The researchers found that the risk of transmission was more prominent within the household and that too before the symptoms of COVID-19 were noted.
Shares of Sun Pharma rose 5 percent intraday on Friday after receiving approval from the Indian drug regulator for clinical trial of its drug on COVID-19 patients.
COVID-19 offers unique opportunity to transform Maharashtra's private healthcare sector, introduce minimum standards of operation
India’s private healthcare is among the most under-regulated in the world, and for the larger part after independence, there has been no overarching attempt to regulate minimum standards and rates of services.
Biotechnology major Biocon on Wednesday said its subsidiary has received approval from the Drugs Controller General of India (DCGI) for a medical device to treat critical COVID-19 patients
WHO promises review of safety data on hydroxychloroquine by mid-June; body suspends trials on coronavirus patients
WHO promised a swift review of data on hydroxychloroquine, probably by mid-June, after safety concerns prompted the group to suspend the malaria drug’s use in a large trial
On 1 May, Glenmark Pharmaceuticals said it has become the first company in India to receive approval from Drug Controller General of India (DCGI) to conduct clinical trials of Favipiravir antiviral tablets for the treatment of COVID-19 patients.
Coronavirus Outbreak: 7,000 beds to be added in Mumbai hospitals over next 14 days to treat COVID-19 patients
By 31 May, Mumbai's bed capacity will be increased by 2,475, including a facility at Bandra (East) which has commenced operations.
Remdesivir preliminary results from NIAID trial published; suggest improvement in recovery time from COVID-19
As per the study, the mortality rate by day 14 was 7.1% in the remdesivir group as compared to 11.9% in the placebo group.
Remdesivir mimics the genetic material of the coronavirus and prevents new virus copies from being produced.
Four out of 14 COVID-19 vaccine candidates may enter clinical trials in next three-five months: Health Minister
Health Minister Harsh Vardhan said, "Till the vaccine is not developed, people should use social vaccines like the mask and social distancing."
Serological studies are starting to be available on child infection history with some suggesting low rates of infection.
First COVID-19 vaccine to enter human trials is safe, well-tolerated and able to generate immune response against virus
The trial was carried out in 108 healthy adults with the vaccine demonstrating promising results after 28 days.
New study suggests PPE made with electroceutical fabric may provide better protection against COVID-19
The electroceutical fabric developed creates a weak electric field that destabilises the viral electrical balance, making it unable to cause infection.
Hydroxychloroquine (HCQ) study shows increased mortality in COVID-19 patients just as ICMR widens its use in India
The study suggests that HCQ should not be used against COVID-19 outside of clinical trials at this point.
COVID-19 vaccine update: Chinese vaccine Phase 1 trial results show some promise but also a few temporary side-effects
As per the study, about 81% of all the participants showed at least one adverse reaction to the vaccine within the first seven days.
Lack of energy, breathlessness and loss of appetite have been reported in people who were previously infected and have recovered from COVID-19.
Children with intellectual disabilities are likely to have difficulty in coping with academic tasks, so you mustn’t push the child excessively.
Indigenous production of diagnostic kits will ensure uninterrupted availability and could be a game-changer in a country like India with a huge population.
Researchers have found a monoclonal antibody in the blood of a SARS patient that has potent therapeutic action against SARS-CoV-2 (COVID-19 causing virus).